Registration Dossier

Diss Factsheets

Toxicological information

Specific investigations: other studies

Currently viewing:

Administrative data

Link to relevant study record(s)

Description of key information

On screening level there is no concern on relevant endocrine modulating properties of this substance.

Additional information

Screening information on endocrine disrupting properties of this substance is available on in vitro and in silico level.


Methacrylamide was negative/ inactive in all 44 in vitro/ in chemico assays performed by US EPA under the ToxCast/ EDSP21 program (18 on estrogen receptor potential, 14 on androgen receptor potential, 10 on thyroid disrupting potential and two on steroidogenesis disrupting potential; US EPA 2021). Respective QSAR models on estrogen and androgen activity (US EPA 2021) and on estrogen, androgen and thyroid activity (Danish EPA, 2021 – partially overlapping with the U.S. EPA models), respectively, indicate that Methacrylamide is inactive as endocrine disruptor.


Thus, on screening level there is no concern on relevant endocrine modulating properties of this substance.